Design of highly potent urea-based, exosite-binding inhibitors selective for glutamate carboxypeptidase II

Journal of Medicinal Chemistry

Volumn 58, Issue 10, 2015, Pages 4357-4363

  Tykvart, Jan ^a,b   Schimer, Jiří ^a,b   Jančařík, Andrej ^a   Bařinková, Jitka ^a   Navrátil, Václav ^a,b   Starková, Jana ^a   Šrámková, Karolína ^a   Konvalinka, Jan ^a,b   Majer, Pavel ^a   Šácha, Pavel ^a,b  

^a INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

2 [ 3 [ 5 [ 6 [ 4 [ 4 ( 4 ACETYLPIPERAZIN 1 YL)PHENYL]PIPERAZIN 1 YL] N ( 4 BROMOBENZYL)NICOTINAMIDO] 1 CARBOXYPENTYL]UREIDO]PENTANEDIOIC; 2 [ 3 [ 5 [N ( 4 BROMOBENZYL) 6 [ 4 [ 4 [ 4 [ 4 CARBOXY 3 ( 6 HYDROXY 3 OXO 3H XANTHEN 9 YL)BENZOYL]PIPERAZIN 1 YL]PHENYL]PIPERAZIN 1 YL]NICOTINAMIDO] 1 CARBOXYPENTYL]UREIDO]PENTANEDIOIC ACID; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II INHIBITOR; UNCLASSIFIED DRUG; ENZYME INHIBITOR; UREA;

ARTICLE; COMPETITIVE INHIBITION; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROGEN BOND; INHIBITION CONSTANT; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; HEK293 CELL LINE; METABOLISM; PROCEDURES; PROTEIN CONFORMATION; SYNTHESIS;

BINDING SITES; CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GLUTAMATE CARBOXYPEPTIDASE II; HEK293 CELLS; HUMANS; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 84930668610     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00278     Document Type: Article

References (25)

1. Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics, 2014 CA Cancer J. Clin 2014, 64, 9-29
2. Foss, C. A.; Mease, R. C.; Cho, S. Y.; Kim, H. J.; Pomper, M. G. GCPII Imaging and Cancer Curr. Med. Chem. 2012, 19, 1346-1359
3. Ghosh, A.; Heston, W. D. W. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer J. Cell. Biochem. 2004, 91, 528-539
4. Huber, F.; Montani, M.; Sulser, T.; Jaggi, R.; Wild, P.; Moch, H.; Gevensleben, H.; Schmid, M.; Wyder, S.; Kristiansen, G. Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer-what has gone wrong? A blueprint for the way forward in biomarker studies Br. J. Cancer 2014, 112, 140-148
5. Tagawa, S. T.; Akhtar, N. H.; Nikolopoulou, A.; Kaur, G.; Robinson, B.; Kahn, R.; Vallabhajosula, S.; Goldsmith, S. J.; Nanus, D. M.; Bander, N. H. Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer Front. Oncol. 2013, 3, 214
6. Haffner, M. C.; Kronberger, I. E.; Ross, J. S.; Sheehan, C. E.; Zitt, M.; Muhlmann, G.; Ofner, D.; Zelger, B.; Ensinger, C.; Yang, X. M. J.; Geley, S.; Margreiter, R.; Bander, N. H. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers Human Pathol. 2009, 40, 1754-1761
7. Chang, S. S.; Reuter, V. E.; Heston, W. D.; Bander, N. H.; Grauer, L. S.; Gaudin, P. B. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature Cancer Res. 1999, 59, 3192-3198
8. Chen, Y.; Pullambhatla, M.; Banerjee, S. R.; Byun, Y.; Stathis, M.; Rojas, C.; Slusher, B. S.; Mease, R. C.; Pomper, M. G. Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen Bioconjugate Chem. 2012, 23, 2377-2385
9. Kovar, J. L.; Cheung, L. L.; Simpson, M. A.; Olive, D. M. Pharmacokinetic and Biodistribution Assessment of a Near Infrared-Labeled PSMA-Specific Small Molecule in Tumor-Bearing Mice Prostate Cancer 2014, 2014, 104248
10. Mease, R. C.; Foss, C. A.; Pomper, M. G. PET imaging in prostate cancer: focus on prostate-specific membrane antigen Curr. Top. Med. Chem. 2013, 13, 951-962
11. Hlouchova, K.; Barinka, C.; Klusak, V.; Sacha, P.; Mlcochova, P.; Majer, P.; Rulisek, L.; Konvalinka, J. Biochemical characterization of human glutamate carboxypeptidase III J. Neurochem. 2007, 101, 682-696
12. Pangalos, M. N.; Neefs, J. M.; Somers, M.; Verhasselt, P.; Bekkers, M.; van der Helm, L.; Fraiponts, E.; Ashton, D.; Gordon, R. D. Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activity J. Biol. Chem. 1999, 274, 8470-8483
13. Collard, F.; Vertommen, D.; Constantinescu, S.; Buts, L.; Van Schaftingen, E. Molecular identification of beta-citrylglutamate hydrolase as glutamate carboxypeptidase 3 J. Biol. Chem. 2011, 286, 38220-38230
14. Miyake, M.; Kume, S.; Kakimoto, Y. Correlation of the level of beta-citryl- l -glutamic acid with spermatogenesis in rat testes Biochim. Biophys. Acta 1982, 719, 495-500
15. Narahara, M.; Tachibana, K.; Adachi, S.; Iwasa, A.; Yukii, A.; Hamada-Kanazawa, M.; Kawai, Y.; Miyake, M. Immunocytochemical localization of beta-citryl- l -glutamate in primary neuronal cells and in the differentiation of P19 mouse embryonal carcinoma cells into neuronal cells Biol. Pharm. Bull. 2000, 23, 1287-1292
16. Hamada-Kanazawa, M.; Kouda, M.; Odani, A.; Matsuyama, K.; Kanazawa, K.; Hasegawa, T.; Narahara, M.; Miyake, M. beta-Citryl- l -glutamate is an endogenous iron chelator that occurs naturally in the developing brain Biol. Pharm. Bull. 2010, 33, 729-737
17. Hamada-Kanazawa, M.; Narahara, M.; Takano, M.; Min, K. S.; Tanaka, K.; Miyake, M. beta-Citryl- l -glutamate acts as an iron carrier to activate aconitase activity Biol. Pharm. Bull. 2011, 34, 1455-1464
18. Tykvart, J.; Schimer, J.; Barinkova, J.; Pachl, P.; Postova-Slavetinska, L.; Majer, P.; Konvalinka, J.; Sacha, P. Rational design of urea-based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery Bioorg. Med. Chem. 2014, 22, 4099-4108
19. Navratil, M.; Ptacek, J.; Sacha, P.; Starkova, J.; Lubkowski, J.; Barinka, C.; Konvalinka, J. Structural and biochemical characterization of the folyl-poly-gamma- l -glutamate hydrolyzing activity of human glutamate carboxypeptidase II FEBS J. 2014, 281, 3228-3242
20. Sacha, P.; Zamecnik, J.; Barinka, C.; Hlouchova, K.; Vicha, A.; Mlcochova, P.; Hilgert, I.; Eckschlager, T.; Konvalinka, J. Expression of glutamate carboxypeptidase II in human brain Neuroscience 2007, 144, 1361-1372
21. Jackson, P. F.; Cole, D. C.; Slusher, B. S.; Stetz, S. L.; Ross, L. E.; Donzanti, B. A.; Trainor, D. A. Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase J. Med. Chem. 1996, 39, 619-622
22. Olszewski, R. T.; Bukhari, N.; Zhou, J.; Kozikowski, A. P.; Wroblewski, J. T.; Shamimi-Noori, S.; Wroblewska, B.; Bzdega, T.; Vicini, S.; Barton, F. B.; Neale, J. H. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR J. Neurochem. 2004, 89, 876-885
23. Wang, H.; Byun, Y.; Barinka, C.; Pullambhatla, M.; Bhang, H. E.; Fox, J. J.; Lubkowski, J.; Mease, R. C.; Pomper, M. G. Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies Bioorg. Med. Chem. Lett. 2010, 20, 392-397
24. Eder, M.; Schafer, M.; Bauder-Wust, U.; Hull, W. E.; Wangler, C.; Mier, W.; Haberkorn, U.; Eisenhut, M. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging Bioconjugate Chem. 2012, 23, 688-697
25. Tykvart, J.; Navratil, V.; Sedlak, F.; Corey, E.; Colombatti, M.; Fracasso, G.; Koukolik, F.; Barinka, C.; Sacha, P.; Konvalinka, J. Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA) Prostate 2014, 74, 1674-1690